Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

If Eli Lilly has its way ... For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now known as ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

If Eli Lilly has its way, this may be the future of obesity ... For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, ...

Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing ...

Eli Lilly and Company discovers ... and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including ...